The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256

PLoS ONE

Volumn 13, Issue 12, 2018, Pages

  Van Diepen, Michiel T ^a   Chapman, Rosamund ^a   Moore, Penny L ^b,c,d   Margolin, Emmanuel ^a   Hermanus, Tandile ^b   Morris, Lynn ^b,c,d   Ximba, Phindile ^a   Rybicki, Edward P ^a   Williamson, Anna Lise ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ADDAVAX; ADJUVANT; ALUMINUM HYDROXIDE; GLYCOPROTEIN GP 140; LECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAP256 VRC26 08; MONOCLONAL ANTIBODY PG16; MONOCLONAL ANTIBODY PGT145; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; POLYSORBATE; SQUALENE;

ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING SITE; BN PAGE; COHORT ANALYSIS; CONTROLLED STUDY; GP140 GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; IMMUNIZATION; LEPORIDAE; MOLECULAR WEIGHT; MUTATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; VIRUS GENE; VIRUS NEUTRALIZATION; BLOOD; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEK293 CELLS; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNIZATION; POLYSORBATES; SQUALENE;

EID: 85058522429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0208310     Document Type: Article

References (49)

1. Baxter C, Abdool Karim S. Combination HIV prevention options for young women in Africa. Afr J AIDS Res. 2016; 15(2):109–21. https://doi.org/10.2989/16085906.2016.1196224 PMID: 27399041.
2. Fauci AS. An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic. JAMA. 2017; 318 (16):1535–6. https://doi.org/10.1001/jama.2017.13505 PMID: 29052689.
3. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47(3):401–9. https://doi.org/10.1086/589862 PMID: 18558875.
4. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275–86. https://doi.org/10.1056/NEJMoa1113425 PMID: 22475592; PubMed Central PMCID: PMCPMC3371689.
5. Kim JH, Excler JL, Michael NL. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015; 66:423–37. https://doi.org/10.1146/annurev-med-052912-123749 PMID: 25341006.
6. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, et al. Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. Cell. 2015; 163(4):988–98. https://doi.org/10.1016/j.cell.2015.10.027 PMID: 26544943; PubMed Central PMCID: PMCPMC5490491.
7. van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology. 2013; 435(1):46–56. https://doi.org/10.1016/j.virol.2012.10.004 PMID: 23217615.
8. Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science. 2017; 358(6359):85–90. https://doi.org/10.1126/science.aan8630 PMID: 28931639.
9. Pegu A, Hessell AJ, Mascola JR, Haigwood NL. Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol Rev. 2017; 275(1):296–312. https://doi.org/10.1111/imr.12511 PMID: 28133803; PubMed Central PMCID: PMCPMC5314445.
10. Haynes BF, Shaw GM, Korber B, Kelsoe G, Sodroski J, Hahn BH, et al. HIV-Host Interactions: Implications for Vaccine Design. Cell Host Microbe. 2016; 19(3):292–303. https://doi.org/10.1016/j.chom.2016.02.002 PMID: 26922989; PubMed Central PMCID: PMCPMC4823811.
11. Havenar-Daughton C, Carnathan DG, Torrents de la Pena A, Pauthner M, Briney B, Reiss SM, et al. Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer. Cell Rep. 2016; 17(9):2195–209. https://doi.org/10.1016/j.celrep.2016.10.085 PMID: 27880897; PubMed Central PMCID: PMCPMC5142765.
12. Moody MA, Pedroza-Pacheco I, Vandergrift NA, Chui C, Lloyd KE, Parks R, et al. Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. Sci Immunol. 2016; 1(1): aag0851. https://doi.org/10.1126/sciimmunol.aag0851 PMID: 28783677; PubMed Central PMCID: PMCPMC5589960.
13. Moore PL, Williamson C. Approaches to the induction of HIV broadly neutralizing antibodies. Curr Opin HIV AIDS. 2016; 11(6):569–75. https://doi.org/10.1097/COH.0000000000000317 PMID: 27559709; PubMed Central PMCID: PMCPMC5130095.
14. Haynes BF, Burton DR. Developing an HIV vaccine. Science. 2017; 355(6330):1129–30. https://doi.org/10.1126/science.aan0662 PMID: 28302812; PubMed Central PMCID: PMCPMC5569908.
15. Burton DR. What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise. Cold Spring Harb Perspect Biol. 2017; 9(11). https://doi.org/10.1101/cshperspect.a030262 PMID: 28159875; PubMed Central PMCID: PMCPMC5540812.
16. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014; 509(7498):55–62. https://doi.org/10.1038/nature13036 PMID: 24590074; PubMed Central PMCID: PMCPMC4395007.
17. Bhiman JN, Anthony C, Doria-Rose NA, Karimanzira O, Schramm CA, Khoza T, et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015; 21 (11):1332–6. https://doi.org/10.1038/nm.3963 PMID: 26457756; PubMed Central PMCID: PMCPMC4637988.
18. Moore PL, Sheward D, Nonyane M, Ranchobe N, Hermanus T, Gray ES, et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol. 2013; 87(9):4882–94. https://doi.org/10.1128/JVI.03424-12 PMID: 23408621; PubMed Central PMCID: PMCPMC3624332.
19. Gorman J, Soto C, Yang MM, Davenport TM, Guttman M, Bailer RT, et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol. 2016; 23(1):81–90. https://doi.org/10.1038/nsmb.3144 PMID: 26689967; PubMed Central PMCID: PMCPMC4833398.
20. Andrabi R, Voss JE, Liang CH, Briney B, McCoy LE, Wu CY, et al. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. Immunity. 2015; 43(5):959–73. https://doi.org/10.1016/j.immuni.2015.10.014 PMID: 26588781; PubMed Central PMCID: PMCPMC4654981.
21. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol. 2014; 21(8):1023–36. https://doi.org/10.1128/CVI. 00230-14 PMID: 24920599; PubMed Central PMCID: PMCPMC4135913.
22. Haynes BF, Mascola JR. The quest for an antibody-based HIV vaccine. Immunol Rev. 2017; 275(1):5–10. https://doi.org/10.1111/imr.12517 PMID: 28133795; PubMed Central PMCID: PMCPMC5384259.
23. Sanders RW, Moore JP. Native-like Env trimers as a platform for HIV-1 vaccine design. Immunol Rev. 2017; 275(1):161–82. https://doi.org/10.1111/imr.12481 PMID: 28133806; PubMed Central PMCID: PMCPMC5299501.
24. Pauthner M, Havenar-Daughton C, Sok D, Nkolola JP, Bastidas R, Boopathy AV, et al. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity. 2017; 46(6):1073–88 e6. https://doi.org/10.1016/j.immuni.2017.05.007 PMID: 28636956; PubMed Central PMCID: PMCPMC5483234.
25. Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, et al. Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 2015; 11(4):539–50. https://doi.org/10.1016/j.celrep.2015.03.047 PMID: 25892233; PubMed Central PMCID: PMCPMC4637274.
26. Apostolico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res. 2016; 2016:1459394. https://doi.org/10.1155/2016/1459394PMID: 27274998; PubMed Central PMCID: PMCPMC4870346.
27. Vaccari M, Gordon SN, Fourati S, Schifanella L, Liyanage NP, Cameron M, et al. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016; 22(7):762–70. https://doi.org/10.1038/nm.4105 PMID: 27239761.
28. McElrath MJ. Adjuvants: tailoring humoral immune responses. Curr Opin HIV AIDS. 2017; 12(3):278–84. https://doi.org/10.1097/COH.0000000000000365 PMID: 28257301; PubMed Central PMCID: PMCPMC5510533.
29. Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine. 2013; 31(33):3363–9. https://doi.org/10.1016/j.vaccine.2013.05.007 PMID: 23684834.
30. Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol. 1995; 6:277–96. PMID: 7551221.
31. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine. 2005; 23(13):1588–95. https://doi.org/10.1016/j.vaccine.2004.07.050 PMID: 15694511.
32. Wu CY, Chang CY, Ma HH, Wang CW, Chen YT, Hsiao PW, et al. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine. 2014; 32 (35):4485–94. https://doi.org/10.1016/j.vaccine.2014.06.043 PMID: 24962757.
33. Ozorowski G, Cupo A, Golabek M, LoPiccolo M, Ketas TA, Cavallary M, et al. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro. J Virol. 2018; 92(13). https://doi.org/10.1128/JVI. 00381-18 PMID: 29669838.
34. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/ V2 domain with broadly neutralizing antibody PG9. Nature. 2011; 480(7377):336–43. https://doi.org/10.1038/nature10696 PMID: 22113616; PubMed Central PMCID: PMCPMC3406929.
35. Tanzer FL, Shephard EG, Palmer KE, Burger M, Williamson AL, Rybicki EP. The porcine circovirus type 1 capsid gene promoter improves antigen expression and immunogenicity in a HIV-1 plasmid vaccine. Virol J. 2011; 8:51. https://doi.org/10.1186/1743-422X-8-51 PMID: 21299896; PubMed Central PMCID: PMCPMC3041773.
36. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, Kalyanaraman R, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol. 2002; 76(17):8875–89. https://doi.org/10.1128/JVI.76.17.8875-8889.2002 PMID: 12163607; PubMed Central PMCID: PMCPMC136973.
37. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, et al. Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol. 2002; 76(6):2606–16. https://doi.org/10.1128/JVI.76.6.2606-2616.2002 PMID: 11861826; PubMed Central PMCID: PMC135977.
38. Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A. 2013; 110(45):18256–61. https://doi.org/10.1073/pnas.1314351110 PMID: 24145402; PubMed Central PMCID: PMC3831437.
39. Kovacs JM, Noeldeke E, Ha HJ, Peng H, Rits-Volloch S, Harrison SC, et al. Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc Natl Acad Sci U S A. 2014; 111(52):18542–7. https://doi.org/10.1073/pnas.1422269112 PMID: 25512514; PubMed Central PMCID: PMC4284565.
40. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol. 2013; 20(7):796–803. https://doi.org/10.1038/nsmb.2594 PMID: 23708606; PubMed Central PMCID: PMCPMC3823233.
41. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209–20. https://doi.org/10.1056/NEJMoa0908492 PMID: 19843557.
42. Sneha Priya R, Veena M, Kalisz I, Whitney S, Priyanka D, LaBranche CC, et al. Antigenicity and immunogenicity of a trimeric envelope protein from an Indian clade C HIV-1 isolate. J Biol Chem. 2015; 290 (14):9195–208. https://doi.org/10.1074/jbc.M114.621185 PMID: 25691567; PubMed Central PMCID: PMCPMC4423705.
43. Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, et al. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. J Infect Dis. 2017; 215(8):1255–63. https://doi.org/10.1093/infdis/ jix099 PMID: 28329190.
44. Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, et al. HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine. J Virol. 2017. https://doi.org/10.1128/JVI.01077-17 PMID: 29021394.
45. Wang C, Hart M, Chui C, Ajuogu A, Brian IJ, de Cassan SC, et al. Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines. J Immunol. 2016; 197 (4):1242–51. https://doi.org/10.4049/jimmunol.1502472 PMID: 27412417; PubMed Central PMCID: PMCPMC4974488.
46. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc Natl Acad Sci U S A. 2014; 111(7):E738–47. https://doi.org/10.1073/pnas.1319512111 PMID: 24550318; PubMed Central PMCID: PMCPMC3932900.
47. Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, et al. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers. PLoS One. 2017; 12(8):e0181886. https://doi.org/10.1371/journal.pone.0181886 PMID: 28792942; PubMed Central PMCID: PMCPMC5549892.
48. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther. 2014; 22(2):464–75. https://doi.org/10.1038/mt.2013.248 PMID: 24166483; PubMed Central PMCID: PMCPMC3911893.
49. Mutua G, Farah B, Langat R, Indangasi J, Ogola S, Onsembe B, et al. Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults. Mol Ther Methods Clin Dev. 2016; 3:16061. https://doi.org/10.1038/mtm.2016.61 PMID: 27617268; PubMed Central PMCID: PMCPMC5006719.